{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:44Z","timestamp":1792784984721,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Strategic International Research Cooperative Program","award":["J150000120"],"award-info":[{"award-number":["J150000120"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The renin-angiotensin system (RAS) is important in the onset and course of cardiovascular, kidney, and metabolic disorders. Previous reports showed that the RAS blockade protects organs and suppress the development of type 2 diabetes mellitus. A novel component of the RAS, namely, chromosome 9 open reading frame 3 (C9orf3), was recently identified, however, its effects are unclear. We evaluated whether the genetic variant of C9orf3 is associated with morbidity of hypertension among subjects with type 2 diabetes. We enrolled 382 subjects with type 2 diabetes, 222 of whom were diagnosed with hypertension. Human leukocyte genomic DNA was isolated and a genetic variant was analyzed for a C\/T variant of C9orf3 (rs4385527) via PCR analysis. The relationship between the genotype and hypertension morbidity among subjects with diabetes was examined. The proportion of the respective C9orf3 genetic variants were as follows 247 CC, 119 CT, and 16 TT. The risk of hypertension was determined to be 1.58, with a 95% confidence interval of 1.11\u20132.27. Moreover, the p value was 0.012 for allelic comparison and for Armitage\u2019s trend test, with the C allele identified as the risk factor. Consequently, hypertension was markedly associated with type 2 diabetes in subjects with the C9orf3 variant, exhibiting a nearly 1.6-fold increased risk. The C variant of a new component of the RAS, C9orf3 (rs4385527) might have a considerable impact on the pathogenesis of hypertension in diabetes.<\/jats:p>","DOI":"10.1038\/s41598-020-73094-0","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T06:05:26Z","timestamp":1601445926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["An association study of C9orf3, a novel component of the renin-angiotensin system, and hypertension in diabetes"],"prefix":"10.1038","volume":"10","author":[{"given":"Mai","family":"Ichikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Konoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasukazu","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamotsu","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"73094_CR1","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.hjh.0000165623.72310.dd","volume":"23","author":"V Dzau","year":"2005","unstructured":"Dzau, V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J. Hypertens. Suppl. 23, S9-17 (2005).","journal-title":"J. Hypertens. Suppl."},{"key":"73094_CR2","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/en.2006-1287","volume":"148","author":"S Wakahara","year":"2007","unstructured":"Wakahara, S. et al. Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. Endocrinology 148, 2453\u20132457. https:\/\/doi.org\/10.1210\/en.2006-1287 (2007).","journal-title":"Endocrinology"},{"key":"73094_CR3","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2337\/diacare.29.04.06.dc05-1873","volume":"29","author":"T Konoshita","year":"2006","unstructured":"Konoshita, T. et al. Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care 29, 848\u2013852 (2006).","journal-title":"Diabetes Care"},{"key":"73094_CR4","first-page":"229","volume":"45","author":"P Corvol","year":"1997","unstructured":"Corvol, P., Soubrier, F. & Jeunemaitre, X. Molecular genetics of the renin-angiotensin-aldosterone system in human hypertension. Pathol. Biol. (Paris) 45, 229\u2013239 (1997).","journal-title":"Pathol. Biol. (Paris)"},{"key":"73094_CR5","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1097\/md.0000000000000354","volume":"93","author":"T Konoshita","year":"2014","unstructured":"Konoshita, T. et al. Determinants of plasma renin activity: role of a human renin gene variant as a genetic factor. Medicine (Baltimore) 93, e354. https:\/\/doi.org\/10.1097\/md.0000000000000354 (2014).","journal-title":"Medicine (Baltimore)"},{"key":"73094_CR6","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.2337\/dc09-0348","volume":"32","author":"T Konoshita","year":"2009","unstructured":"Konoshita, T. et al. Genetic variant of the renin-angiotensin system and diabetes influences blood pressure response to angiotensin receptor blockers. Diabetes Care 32, 1485\u20131490. https:\/\/doi.org\/10.2337\/dc09-0348 (2009).","journal-title":"Diabetes Care"},{"key":"73094_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861\u2013869. https:\/\/doi.org\/10.1056\/NEJMoa011161 (2001).","journal-title":"N. Engl. J. Med."},{"key":"73094_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851\u2013860. https:\/\/doi.org\/10.1056\/NEJMoa011303 (2001).","journal-title":"N. Engl. J. Med."},{"key":"73094_CR9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving, H. H. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345, 870\u2013878. https:\/\/doi.org\/10.1056\/NEJMoa011489 (2001).","journal-title":"N. Engl. J. Med."},{"key":"73094_CR10","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"CD Furberg","year":"2002","unstructured":"Furberg, C. D. et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981\u20132997 (2002).","journal-title":"JAMA"},{"key":"73094_CR11","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/s0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius, S. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363, 2022\u20132031. https:\/\/doi.org\/10.1016\/s0140-6736(04)16451-9 (2004).","journal-title":"Lancet"},{"key":"73094_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/hypertensionaha.107.098475","volume":"51","author":"T Ogihara","year":"2008","unstructured":"Ogihara, T. et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 51, 393\u2013398. https:\/\/doi.org\/10.1161\/hypertensionaha.107.098475 (2008).","journal-title":"Hypertension"},{"key":"73094_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00592-014-0561-7","volume":"51","author":"M Ichikawa","year":"2014","unstructured":"Ichikawa, M. et al. Genetic variant of the renin-angiotensin system and prevalence of type 2 diabetes mellitus: a modest but significant effect of aldosterone synthase. Acta Diabetol. 51, 595\u2013599. https:\/\/doi.org\/10.1007\/s00592-014-0561-7 (2014).","journal-title":"Acta Diabetol."},{"key":"73094_CR14","doi-asserted-by":"publisher","first-page":"F1024","DOI":"10.1152\/ajprenal.00221.2005","volume":"290","author":"XC Li","year":"2006","unstructured":"Li, X. C., Campbell, D. J., Ohishi, M., Yuan, S. & Zhuo, J. L. AT1 receptor-activated signaling mediates angiotensin IV-induced renal cortical vasoconstriction in rats. Am. J. Physiol. Renal Physiol. 290, F1024-1033. https:\/\/doi.org\/10.1152\/ajprenal.00221.2005 (2006).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"73094_CR15","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/jcb.21497","volume":"103","author":"R Axton","year":"2008","unstructured":"Axton, R., Wallis, J. A., Taylor, H., Hanks, M. & Forrester, L. M. Aminopeptidase O contains a functional nucleolar localization signal and is implicated in vascular biology. J. Cell. Biochem. 103, 1171\u20131182. https:\/\/doi.org\/10.1002\/jcb.21497 (2008).","journal-title":"J. Cell. Biochem."},{"key":"73094_CR16","doi-asserted-by":"publisher","first-page":"e0140695","DOI":"10.1371\/journal.pone.0140695","volume":"10","author":"Y Xu","year":"2015","unstructured":"Xu, Y. et al. Systematic evaluation of genetic variants for polycystic ovary syndrome in a Chinese population. PLoS ONE 10, e0140695. https:\/\/doi.org\/10.1371\/journal.pone.0140695 (2015).","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"73094_CR17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/13697130903003842","volume":"12","author":"E Carmina","year":"2009","unstructured":"Carmina, E. Cardiovascular risk and events in polycystic ovary syndrome. Climacteric 12(Suppl 1), 22\u201325 (2009).","journal-title":"Climacteric"},{"key":"73094_CR18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1590\/S0004-27302009000200014","volume":"53","author":"E Kandaraki","year":"2009","unstructured":"Kandaraki, E., Christakou, C. & Diamanti-Kandarakis, E. Metabolic syndrome and polycystic ovary syndrome\u2026 and vice versa. Arq. Bras. Endocrinol. Metabol. 53, 227\u2013237 (2009).","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"73094_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/ajh\/hpu251","volume":"28","author":"AE Joham","year":"2015","unstructured":"Joham, A. E., Boyle, J. A., Zoungas, S. & Teede, H. J. Hypertension in reproductive-aged women with polycystic ovary syndrome and association with obesity. Am. J. Hypertens. 28, 847\u2013851. https:\/\/doi.org\/10.1093\/ajh\/hpu251 (2015).","journal-title":"Am. J. Hypertens."},{"key":"73094_CR20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.diabres.2011.03.012","volume":"93","author":"WHO","year":"2011","unstructured":"WHO. Report of a World Health Organization consultation. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Diabetes Res. Clin. Pract. 93, 299\u2013309 (2011).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"73094_CR21","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura, S. et al. The Japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2019). Hypertens. Res. 42, 1235\u20131481. https:\/\/doi.org\/10.1038\/s41440-019-0284-9 (2019).","journal-title":"Hypertens. Res."},{"key":"73094_CR22","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(95)91088-3","volume":"345","author":"PN Harden","year":"1995","unstructured":"Harden, P. N. et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 345, 1540\u20131542 (1995).","journal-title":"Lancet"},{"key":"73094_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/nejm199503163321103","volume":"332","author":"K Lindpaintner","year":"1995","unstructured":"Lindpaintner, K. et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N. Engl. J. Med. 332, 706\u2013711. https:\/\/doi.org\/10.1056\/nejm199503163321103 (1995).","journal-title":"N. Engl. J. Med."},{"key":"73094_CR24","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.2337\/diab.45.9.1204","volume":"45","author":"DG Fogarty","year":"1996","unstructured":"Fogarty, D. G. et al. A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Diabetes 45, 1204\u20131208 (1996).","journal-title":"Diabetes"},{"key":"73094_CR25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/ajkd.2001.20595","volume":"37","author":"T Konoshita","year":"2001","unstructured":"Konoshita, T. et al. Effect of ACE gene polymorphism on age at renal death in polycystic kidney disease in Japan. Am. J. Kidney Dis 37, 113\u2013118 (2001).","journal-title":"Am. J. Kidney Dis"},{"key":"73094_CR26","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1056\/nejm199406093302301","volume":"330","author":"M Caulfield","year":"1994","unstructured":"Caulfield, M. et al. Linkage of the angiotensinogen gene to essential hypertension. N. Engl. J. Med. 330, 1629\u20131633. https:\/\/doi.org\/10.1056\/nejm199406093302301 (1994).","journal-title":"N. Engl. J. Med."},{"key":"73094_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/359641a0","volume":"359","author":"F Cambien","year":"1992","unstructured":"Cambien, F. et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359, 641\u2013644. https:\/\/doi.org\/10.1038\/359641a0 (1992).","journal-title":"Nature"},{"key":"73094_CR28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0092-8674(92)90275-H","volume":"71","author":"X Jeunemaitre","year":"1992","unstructured":"Jeunemaitre, X. et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 71, 169\u2013180 (1992).","journal-title":"Cell"},{"key":"73094_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ng.834","volume":"43","author":"N Kato","year":"2011","unstructured":"Kato, N. et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in East Asians. Nat. Genet. 43, 531\u2013538. https:\/\/doi.org\/10.1038\/ng.834 (2011).","journal-title":"Nat. Genet."},{"key":"73094_CR30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3109\/09513590.2013.769513","volume":"29","author":"S Arefi","year":"2013","unstructured":"Arefi, S., Mottaghi, S. & Sharifi, A. M. Studying the correlation of renin-angiotensin-system (RAS) components and insulin resistance in polycystic ovary syndrome (PCOs). Gynecol. Endocrinol. 29, 470\u2013473. https:\/\/doi.org\/10.3109\/09513590.2013.769513 (2013).","journal-title":"Gynecol. Endocrinol."},{"key":"73094_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.1976.56.1.1","volume":"56","author":"JO Davis","year":"1976","unstructured":"Davis, J. O. & Freeman, R. H. Mechanisms regulating renin release. Physiol. Rev. 56, 1\u201356. https:\/\/doi.org\/10.1152\/physrev.1976.56.1.1 (1976).","journal-title":"Physiol. Rev."},{"key":"73094_CR32","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/nejm199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456\u20131462. https:\/\/doi.org\/10.1056\/nejm199311113292004 (1993).","journal-title":"N. Engl. J. Med."},{"key":"73094_CR33","doi-asserted-by":"crossref","unstructured":"33Shen, J. et al. Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease. J. Renin. Angiotensin. Aldosterone Syst.17. 10.1177\/1470320316656481 (2016).","DOI":"10.1177\/1470320316656481"},{"key":"73094_CR34","doi-asserted-by":"publisher","first-page":"147032031880300","DOI":"10.1177\/1470320318803009","volume":"19","author":"CM Chen","year":"2018","unstructured":"Chen, C. M., Juan, S. H. & Chou, H. C. Hyperglycemia activates the renin-angiotensin system and induces epithelial-mesenchymal transition in streptozotocin-induced diabetic kidneys. J. Renin. Angiotensin. Aldosterone Syst. 19, 1470320318803009. https:\/\/doi.org\/10.1177\/1470320318803009 (2018).","journal-title":"J. Renin. Angiotensin. Aldosterone Syst."},{"key":"73094_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00395-016-0591-0","volume":"112","author":"M Blumensatt","year":"2017","unstructured":"Blumensatt, M. et al. Secretory products from epicardial adipose tissue from patients with type 2 diabetes impair mitochondrial beta-oxidation in cardiomyocytes via activation of the cardiac renin-angiotensin system and induction of miR-208a. Basic Res. Cardiol. 112, 2. https:\/\/doi.org\/10.1007\/s00395-016-0591-0 (2017).","journal-title":"Basic Res. Cardiol."},{"key":"73094_CR36","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1681\/ASN.V1081778","volume":"10","author":"JA Miller","year":"1999","unstructured":"Miller, J. A. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J. Am. Soc. Nephrol. 10, 1778\u20131785 (1999).","journal-title":"J. Am. Soc. Nephrol."},{"key":"73094_CR37","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.cellsig.2010.07.012","volume":"22","author":"R Day","year":"2010","unstructured":"Day, R. T. et al.. Acute hyperglycemia rapidly stimulates VEGF mRNA translation in the kidney. Role of angiotensin type 2 receptor (AT2). Cell Signal. 22, 1849\u20131857. https:\/\/doi.org\/10.1016\/j.cellsig.2010.07.012 (2010).","journal-title":"Cell Signal."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73094-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73094-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73094-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T15:14:27Z","timestamp":1670339667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73094-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73094"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73094-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"22 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16111"}}